{
    "Trade/Device Name(s)": [
        "LZI Methamphetamine Enzyme Immunoassay",
        "LZI Methamphetamine Drugs of Abuse (DAU) Calibrators",
        "LZI Methamphetamine Drugs of Abuse (DAU) Controls"
    ],
    "Submitter Information": "Lin-Zhi International, Inc.",
    "510(k) Number": "K113661",
    "Predicate Device Reference 510(k) Number(s)": [
        "K102210"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LAF",
        "DLJ",
        "LAS"
    ],
    "Summary Letter Date": "December 12, 2011",
    "Summary Letter Received Date": "December 13, 2011",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3610",
        "21CFR862.3200",
        "21CFR862.3280"
    ],
    "Regulation Name(s)": [
        "Methamphetamine Test System",
        "Drug Specific Calibrators",
        "Drug Specific Controls"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "d-methamphetamine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Hitachi 717 automated clinical chemistry analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)"
    ],
    "Methodologies": [
        "Homogeneous enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for LZI Methamphetamine Enzyme Immunoassay and associated calibrators and controls for qualitative and semi-quantitative detection of d-methamphetamine in human urine using automated chemistry analyzers.",
    "Indications for Use Summary": "Intended for qualitative and semi-quantitative determination of d-methamphetamine in human urine at a 500 ng/mL cutoff; for professional use with automated clinical chemistry analyzers as a preliminary screening test, requiring confirmatory methods for positive results.",
    "fda_folder": "Toxicology"
}